Frank Mottola Biography and Net Worth

SVP, GMP Operations, IT and Regulatory Affairs of Supernus Pharmaceuticals

Frank Mottola was promoted to Senior Vice President of Quality, GMP Operations and Information Technology in 2020. Previously, he served as Vice President of Quality, GMP Operations and Information Technology beginning in 2017. From 2014-2017, he served as Vice President of Quality and GMP Operations. Initially he joined Supernus as Director of Quality in 2005, responsible for initiating Quality Systems at the company’s inception. Prior to that time, Mr. Mottola was the Director of Quality at Able Laboratories and previously held positions at Ortho Clinical Diagnostics (Johnson & Johnson). He has 24 years of experience in the pharmaceutical industry and holds a Bachelor’s degree in Biology and Business Administration while attending Rutgers University and Walden University.

What is Frank Mottola's net worth?: The estimated net worth of Frank Mottola is at least $257,963.80 as of November 7th, 2024. Mr. Mottola owns 8,200 shares of Supernus Pharmaceuticals stock worth more than $257,964 as of March 14th. This net worth evaluation does not reflect any other investments that Mr. Mottola may own. Additionally, Mr. Mottola receives a salary of $490,870.00 as SVP, GMP Operations, IT and Regulatory Affairs at Supernus Pharmaceuticals. Learn More about Frank Mottola's net worth.
How old is Frank Mottola?: Mr. Mottola is currently 52 years old. There are 6 older executives and no younger executives at Supernus Pharmaceuticals. The oldest executive at Supernus Pharmaceuticals is Ms. Tami T. Martin Esq., R.N., Senior Vice President of Regulatory Affairs, who is 69 years old. Learn More on Frank Mottola's age.
What is Frank Mottola's salary?: As the SVP, GMP Operations, IT and Regulatory Affairs of Supernus Pharmaceuticals, Inc., Mr. Mottola earns $490,870.00 per year. There are 5 executives that earn more than Mr. Mottola. The highest earning executive at Supernus Pharmaceuticals is Mr. Jack A. Khattar, Founder, President, CEO, Secretary & Director, who commands a salary of $1,630,000.00 per year. Learn More on Frank Mottola's salary.
How do I contact Frank Mottola?: The corporate mailing address for Mr. Mottola and other Supernus Pharmaceuticals executives is 1550 E GUDE DR, ROCKVILLE MD, 20850. Supernus Pharmaceuticals can also be reached via phone at (301) 838-2500 and via email at gpatrick@supernus.com. Learn More on Frank Mottola's contact information.
Has Frank Mottola been buying or selling shares of Supernus Pharmaceuticals?: Frank Mottola has not been actively trading shares of Supernus Pharmaceuticals in the last ninety days. Most recently, Frank Mottola sold 15,000 shares of the business's stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $36.98, for a transaction totalling $554,700.00. Following the completion of the sale, the senior vice president now directly owns 8,200 shares of the company's stock, valued at $303,236. Learn More on Frank Mottola's trading history.
Who are Supernus Pharmaceuticals' active insiders?: Supernus Pharmaceuticals' insider roster includes Padmanabh Bhatt (Senior Vice President, Chief Scientific Officer, Intellectual Property), Georges Gemayel (Director), Frederick Hudson (Director), Jack Khattar (President and Chief Executive Officer, Director), Frank Mottola (SVP, GMP Operations, IT and Regulatory Affairs), and Jonathan Rubin (Senior Vice President, Chief Medical Officer, Research & Development). Learn More on Supernus Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Supernus Pharmaceuticals?: In the last twelve months, insiders at the specialty pharmaceutical company sold shares 8 times. They sold a total of 192,172 shares worth more than $7,048,693.06. The most recent insider tranaction occured on February, 21st when SVP Jonathan Rubin sold 927 shares worth more than $36,292.05. Insiders at Supernus Pharmaceuticals own 9.3% of the company. Learn More about insider trades at Supernus Pharmaceuticals.
Information on this page was last updated on 2/21/2025.

Frank Mottola Insider Trading History at Supernus Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/7/2024	Sell	15,000	$36.98	$554,700.00	8,200
11/14/2023	Sell	1,110	$28.13	$31,224.30	5,681
3/14/2023	Sell	4,780	$35.99	$172,032.20	4,737

Frank Mottola Buying and Selling Activity at Supernus Pharmaceuticals

Supernus Pharmaceuticals Company Overview

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.

Today's Range

Now: $31.46

$30.30

50 Day Range

MA: $36.44

$31.38

$40.00

2 Week Range

Now: $31.46

$25.53

$40.28

Volume

337 shs

Average Volume

553,427 shs

Market Capitalization

$1.76 billion

P/E Ratio

28.98

Dividend Yield

N/A

Beta

0.83

Frank Mottola Biography and Net Worth

What is Frank Mottola's net worth?

How old is Frank Mottola?

What is Frank Mottola's salary?

How do I contact Frank Mottola?

Has Frank Mottola been buying or selling shares of Supernus Pharmaceuticals?

Who are Supernus Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Supernus Pharmaceuticals?